Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Edwards Lifesciences (EW) Asset Writedowns and Impairment (2017 - 2026)

Edwards Lifesciences has reported Asset Writedowns and Impairment over the past 3 years, most recently at $146.9 million for Q4 2025.

For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $146.9 million; the TTM value through Dec 2025 reached $234.0 million, changed N/A, while the annual FY2025 figure was $186.9 million, N/A changed from the prior year.
Asset Writedowns and Impairment for Q4 2025 was $146.9 million at Edwards Lifesciences, up from $40.0 million in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $146.9 million in Q4 2025 and troughed at $40.0 million in Q3 2025.